Real-world clinical outcomes and treatment patterns in patients with MDD treated with vortioxetine: a retrospective study
Abstract Background This study included evaluation of the effectiveness of vortioxetine, a treatment for adults with major depressive disorder (MDD), using patient-reported outcome measures (PROMs) in a real-world setting. Methods This retrospective chart review analyzed the care experiences of adul...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-12-01
|
| Series: | BMC Psychiatry |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12888-023-05439-8 |
| _version_ | 1827581427698368512 |
|---|---|
| author | Brandon T. McDaniel Victor Cornet Jeanne Carroll Lambros Chrones Joseph Chudzik Jeanette Cochran Shion Guha Debra F. Lawrence Maggie McCue Sara Sarkey Betty Lorenz Jay Fawver |
| author_facet | Brandon T. McDaniel Victor Cornet Jeanne Carroll Lambros Chrones Joseph Chudzik Jeanette Cochran Shion Guha Debra F. Lawrence Maggie McCue Sara Sarkey Betty Lorenz Jay Fawver |
| author_sort | Brandon T. McDaniel |
| collection | DOAJ |
| description | Abstract Background This study included evaluation of the effectiveness of vortioxetine, a treatment for adults with major depressive disorder (MDD), using patient-reported outcome measures (PROMs) in a real-world setting. Methods This retrospective chart review analyzed the care experiences of adult patients with a diagnosis of MDD from Parkview Physicians Group – Mind-Body Medicine, Midwestern United States. Patients with a prescription for vortioxetine, an initial baseline visit, and ≥ 2 follow-up visits within 16 weeks from September 2014 to December 2018 were included. The primary outcome measure was effectiveness of vortioxetine on depression severity as assessed by change in Patient Health Questionnaire-9 (PHQ-9) scores ~ 12 weeks after initiation of vortioxetine. Secondary outcomes included changes in depression-related symptoms (i.e., sexual dysfunction, sleep disturbance, cognitive function, work/social function), clinical characteristics, response, remission, and medication persistence. Clinical narrative notes were also analyzed to examine sleep disturbance, sexual dysfunction, appetite, absenteeism, and presenteeism. All outcomes were examined at index (start of vortioxetine) and at ~ 12 weeks, and mean differences were analyzed using pairwise t tests. Results A total of 1242 patients with MDD met inclusion criteria, and 63.9% of these patients had ≥ 3 psychiatric diagnoses and 65.9% were taking ≥ 3 medications. PHQ-9 mean scores decreased significantly from baseline to week 12 (14.15 ± 5.8 to 9.62 ± 6.03, respectively; p < 0.001). At week 12, the response and remission rates in all patients were 31.0% and 23.1%, respectively, and 67% continued vortioxetine treatment. Overall, results also showed significant improvements by week 12 in anxiety (p < 0.001), sexual dysfunction (p < 0.01), sleep disturbance (p < 0.01), cognitive function (p < 0.001), work/social functioning (p = 0.021), and appetite (p < 0.001). A significant decrease in presenteeism was observed at week 12 (p < 0.001); however, no significant change was observed in absenteeism (p = 0.466). Conclusions Using PROMs, our study results suggest that adults with MDD prescribed vortioxetine showed improvement in depressive symptoms in the context of a real-world clinical practice setting. These patients had multiple comorbid psychiatric and physical diagnoses and multiple previous antidepressant treatments had failed. |
| first_indexed | 2024-03-08T22:36:18Z |
| format | Article |
| id | doaj.art-461fc965bd8d48ea88008ac5ac8f8858 |
| institution | Directory Open Access Journal |
| issn | 1471-244X |
| language | English |
| last_indexed | 2024-03-08T22:36:18Z |
| publishDate | 2023-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Psychiatry |
| spelling | doaj.art-461fc965bd8d48ea88008ac5ac8f88582023-12-17T12:26:27ZengBMCBMC Psychiatry1471-244X2023-12-0123111410.1186/s12888-023-05439-8Real-world clinical outcomes and treatment patterns in patients with MDD treated with vortioxetine: a retrospective studyBrandon T. McDaniel0Victor Cornet1Jeanne Carroll2Lambros Chrones3Joseph Chudzik4Jeanette Cochran5Shion Guha6Debra F. Lawrence7Maggie McCue8Sara Sarkey9Betty Lorenz10Jay Fawver11Parkview Mirro Center for Research and InnovationParkview Mirro Center for Research and InnovationParkview Mirro Center for Research and InnovationTakeda Pharmaceuticals U.S.A., IncParkview Mirro Center for Research and InnovationParkview Physicians Group − Mind-Body MedicineParkview Mirro Center for Research and InnovationTakeda Pharmaceuticals U.S.A., IncTakeda Pharmaceuticals U.S.A., IncTakeda Pharmaceuticals U.S.A., IncTakeda Pharmaceuticals U.S.A., IncParkview Physicians Group − Mind-Body MedicineAbstract Background This study included evaluation of the effectiveness of vortioxetine, a treatment for adults with major depressive disorder (MDD), using patient-reported outcome measures (PROMs) in a real-world setting. Methods This retrospective chart review analyzed the care experiences of adult patients with a diagnosis of MDD from Parkview Physicians Group – Mind-Body Medicine, Midwestern United States. Patients with a prescription for vortioxetine, an initial baseline visit, and ≥ 2 follow-up visits within 16 weeks from September 2014 to December 2018 were included. The primary outcome measure was effectiveness of vortioxetine on depression severity as assessed by change in Patient Health Questionnaire-9 (PHQ-9) scores ~ 12 weeks after initiation of vortioxetine. Secondary outcomes included changes in depression-related symptoms (i.e., sexual dysfunction, sleep disturbance, cognitive function, work/social function), clinical characteristics, response, remission, and medication persistence. Clinical narrative notes were also analyzed to examine sleep disturbance, sexual dysfunction, appetite, absenteeism, and presenteeism. All outcomes were examined at index (start of vortioxetine) and at ~ 12 weeks, and mean differences were analyzed using pairwise t tests. Results A total of 1242 patients with MDD met inclusion criteria, and 63.9% of these patients had ≥ 3 psychiatric diagnoses and 65.9% were taking ≥ 3 medications. PHQ-9 mean scores decreased significantly from baseline to week 12 (14.15 ± 5.8 to 9.62 ± 6.03, respectively; p < 0.001). At week 12, the response and remission rates in all patients were 31.0% and 23.1%, respectively, and 67% continued vortioxetine treatment. Overall, results also showed significant improvements by week 12 in anxiety (p < 0.001), sexual dysfunction (p < 0.01), sleep disturbance (p < 0.01), cognitive function (p < 0.001), work/social functioning (p = 0.021), and appetite (p < 0.001). A significant decrease in presenteeism was observed at week 12 (p < 0.001); however, no significant change was observed in absenteeism (p = 0.466). Conclusions Using PROMs, our study results suggest that adults with MDD prescribed vortioxetine showed improvement in depressive symptoms in the context of a real-world clinical practice setting. These patients had multiple comorbid psychiatric and physical diagnoses and multiple previous antidepressant treatments had failed.https://doi.org/10.1186/s12888-023-05439-8Depression severityMajor depressive disorderPatient-reported outcome measuresReal-world clinical practice settingVortioxetineComorbid psychiatric diagnoses |
| spellingShingle | Brandon T. McDaniel Victor Cornet Jeanne Carroll Lambros Chrones Joseph Chudzik Jeanette Cochran Shion Guha Debra F. Lawrence Maggie McCue Sara Sarkey Betty Lorenz Jay Fawver Real-world clinical outcomes and treatment patterns in patients with MDD treated with vortioxetine: a retrospective study BMC Psychiatry Depression severity Major depressive disorder Patient-reported outcome measures Real-world clinical practice setting Vortioxetine Comorbid psychiatric diagnoses |
| title | Real-world clinical outcomes and treatment patterns in patients with MDD treated with vortioxetine: a retrospective study |
| title_full | Real-world clinical outcomes and treatment patterns in patients with MDD treated with vortioxetine: a retrospective study |
| title_fullStr | Real-world clinical outcomes and treatment patterns in patients with MDD treated with vortioxetine: a retrospective study |
| title_full_unstemmed | Real-world clinical outcomes and treatment patterns in patients with MDD treated with vortioxetine: a retrospective study |
| title_short | Real-world clinical outcomes and treatment patterns in patients with MDD treated with vortioxetine: a retrospective study |
| title_sort | real world clinical outcomes and treatment patterns in patients with mdd treated with vortioxetine a retrospective study |
| topic | Depression severity Major depressive disorder Patient-reported outcome measures Real-world clinical practice setting Vortioxetine Comorbid psychiatric diagnoses |
| url | https://doi.org/10.1186/s12888-023-05439-8 |
| work_keys_str_mv | AT brandontmcdaniel realworldclinicaloutcomesandtreatmentpatternsinpatientswithmddtreatedwithvortioxetinearetrospectivestudy AT victorcornet realworldclinicaloutcomesandtreatmentpatternsinpatientswithmddtreatedwithvortioxetinearetrospectivestudy AT jeannecarroll realworldclinicaloutcomesandtreatmentpatternsinpatientswithmddtreatedwithvortioxetinearetrospectivestudy AT lambroschrones realworldclinicaloutcomesandtreatmentpatternsinpatientswithmddtreatedwithvortioxetinearetrospectivestudy AT josephchudzik realworldclinicaloutcomesandtreatmentpatternsinpatientswithmddtreatedwithvortioxetinearetrospectivestudy AT jeanettecochran realworldclinicaloutcomesandtreatmentpatternsinpatientswithmddtreatedwithvortioxetinearetrospectivestudy AT shionguha realworldclinicaloutcomesandtreatmentpatternsinpatientswithmddtreatedwithvortioxetinearetrospectivestudy AT debraflawrence realworldclinicaloutcomesandtreatmentpatternsinpatientswithmddtreatedwithvortioxetinearetrospectivestudy AT maggiemccue realworldclinicaloutcomesandtreatmentpatternsinpatientswithmddtreatedwithvortioxetinearetrospectivestudy AT sarasarkey realworldclinicaloutcomesandtreatmentpatternsinpatientswithmddtreatedwithvortioxetinearetrospectivestudy AT bettylorenz realworldclinicaloutcomesandtreatmentpatternsinpatientswithmddtreatedwithvortioxetinearetrospectivestudy AT jayfawver realworldclinicaloutcomesandtreatmentpatternsinpatientswithmddtreatedwithvortioxetinearetrospectivestudy |